VEGF165, but not VEGF189, stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo

Molecular Cancer Research

Volumn 5, Issue 11, 2007, Pages 1125-1132

  Zhou, Zhichao ^a   Reddy, Krishna ^a   Guan, Hui ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; FLUORESCENT DYE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN 189;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CONTROLLED STUDY; EWING SARCOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; CELL MOVEMENT; ENDOTHELIAL CELLS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; SARCOMA, EWING'S; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; MUS MUSCULUS;

EID: 36248979685     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0174     Document Type: Article

References (15)

1. Huvos AG. Ewing's sarcoma. In: Huvos AG, editor. Bone tumors: diagnosis, treatment and prognosis. 2nd ed. Philadelphia: Saunders; 1991. p. 523-52.
2. Zhou Z, Zhou RR, Guan H, Bucana CD, Kleinerman ES. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2003;2:1313-9.
3. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-53.
4. Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 2001;36:601-4.
5. Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W, Schweigerer L. Quantification of angiogenesis stimulator in children with sold malignancies. Int J Cancer 2001;92:756-60.
6. Bacci G, Picci P, Ferrari S, et al. Neoajuvant chemotherapy for Ewing's sarcoma of bone. Cancer 1998;82:1174-83.
7. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing's tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol 1998;9:275-81.
8. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
9. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001;52:61-6.
10. + stem cell into the expanding tumor vasculature. Int J Cancer 2006;119:839-46.
11. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002;8:3622-7.
12. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11:2662-9.
13. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
14. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
15. Graham FL, Prevec L. Manipulation of adenovirus vector. Gene transfer and expression protocol. Vol. 7. Clifton (NJ): The Humana Press; 1991. p. 109-28.